SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study
Reuters
Sep 02
SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study
SeaStar Medical Holding Corporation has announced the results of a recently published health economic study concerning the QUELIMMUNE therapy, aimed at treating pediatric Acute Kidney Injury (AKI). The study, published in the Journal of Medical Economics, indicates significant cost savings, estimating a reduction of approximately 18% per hospitalization. The economic analysis projects a cost savings of $69,146 per hospitalization when QUELIMMUNE is used, compared to standard treatments. This potential cost reduction is attributed to shorter hospital stays and increased survival rates, as clinical data shows a 77% survival rate in patients treated with QUELIMMUNE. The therapy, approved by the FDA under a Humanitarian Device Exemption in 2024, is designed for pediatric patients with AKI due to sepsis or septic conditions. SeaStar Medical is also conducting the NEUTRALIZE-AKI pivotal trial to further assess the safety and efficacy of its SCD therapy in ICU patients with AKI.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521251-en) on September 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.